ALSO NOTED: Canada's drug market slowing; GSK files for Promacta approval;

> The Canadian pharma market has slowed to a growth level of 6 percent to 6.5 percent, down from a five-year average of 8.4 percent. Report

> GlaxoSmithKline submitted an NDA for Promacta, a platelet growth factor designed to treat thrombocytopenic purpura. Report

> Valeant Pharmaceuticals says it will sell its hepatitis C drug Infergen to Three Rivers Pharmaceuticals doe about $91.3 million. Report

> Par Pharmaceutical says its year-end profits will be at least $1.45 per share; previously, the generics maker had said it expected earnings of $1.35 to $1.50. Report

> Idera is pocketing a $40 million up front fee from Merck KGaA and hopes to make an additional $381 million in milestones from licensing its technology for cancer therapies. Report

> In a deal that starts small but has a big upside, Santaris Pharma has forged a $700 million development pact with GlaxoSmithKline to develop new antiviral meds. Report

> Boston-based venture capitalist Roger Kitterman has been able to coax investors to back badly needed therapies with none of the big upside that most would demand. Report

> The Wall Street Journal health blog pokes fun at Bystolic, the newly-approved beta blocker from Forest Laboratories and Mylan, as the ultimate "me-too" drug. Report

And Finally… Harvard Business School researchers have identified four types of healthcare consumers, each of which responds to entirely different marketing approaches. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.